New strategy for MS treatment with autoantigen-modified liposomes and their therapeutic effect
Authors:
Open Access
- 1 July 2021
- journal article
- research article
- Published by Elsevier in Journal of Controlled Release
- Vol. 335, 389-397
Abstract
No abstract availableKeywords
Funding Information
- Takeda Science Foundation
- Mochida Memorial Foundation for Medical and Pharmaceutical Research
- Japan Society for the Promotion of Science
This publication has 50 references indexed in Scilit:
- Development of tissue factor-targeted liposomes for effective drug delivery to stroma-rich tumorsJournal of Controlled Release, 2020
- Treatment and management of cognitive dysfunction in patients with multiple sclerosisNature Reviews Neurology, 2020
- Recent advancements in liposome technologyAdvanced Drug Delivery Reviews, 2020
- Drug-associated progressive multifocal leukoencephalopathy in multiple sclerosis patientsMultiple Sclerosis Journal, 2018
- Specific delivery of an immunosuppressive drug to splenic B cells by antigen-modified liposomes and its antiallergic effectJournal of Drug Targeting, 2016
- Nano-Drugs Based on Nano Sterically Stabilized Liposomes for the Treatment of Inflammatory Neurodegenerative DiseasesPLOS ONE, 2015
- Suppression of immune response by antigen-modified liposomes encapsulating model agents: A novel strategy for the treatment of allergyJournal of Controlled Release, 2013
- Risk of Natalizumab-Associated Progressive Multifocal LeukoencephalopathyNew England Journal of Medicine, 2012
- Liposomal Encapsulation of Glucocorticoids Alters Their Mode of Action in the Treatment of Experimental Autoimmune EncephalomyelitisThe Journal of Immunology, 2011
- Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS)British Journal of Pharmacology, 2011